Brief: Ngm Bio Presents Updated Preliminary Findings For A Subgroup Of Patients With Advanced Prostate Cancer

NGM Biopharmaceuticals

06/09/2022 13:21

Sept 6 (Reuters) - NGM Biopharmaceuticals Inc  NGM.O :
    * NGM BIO PRESENTS UPDATED PRELIMINARY FINDINGS FOR A
SUBGROUP OF
PATIENTS WITH ADVANCED PROSTATE CANCER FROM THE ONGOING PHASE 1A
DOSE ESCALATION TRIAL OF NGM120 IN PATIENTS WITH ADVANCED SOLID
TUMORS AT THE ESMO ANNUAL CONGRESS
    * NGM BIO PRESENTS UPDATED PRELIMINARY FINDINGS FOR A
SUBGROUP OF
PATIENTS WITH ADVANCED PROSTATE CANCER FROM THE ONGOING PHASE 1A
DOSE ESCALATION TRIAL OF NGM120 IN PATIENTS WITH ADVANCED SOLID
TUMORS AT THE ESMO ANNUAL CONGRESS
    * NGM BIOPHARMACEUTICALS INC - NGM120 HAS BEEN WELL
TOLERATED TO
DATE IN PATIENTS IN PHASE 1A STUDY WITH NO DOSE-LIMITING
TOXICITIES
    * NGM BIOPHARMACEUTICALS INC - TWO PATIENTS EXPERIENCED
REDUCTIONS
IN PROSTATE-SPECIFIC ANTIGEN (PSA) LEVELS
    * NGM BIOPHARMACEUTICALS INC - TWO OF FIVE PROSTATE CANCER
PATIENTS IN PHASE 1A TRIAL DEMONSTRATED DISEASE CONTROL

Source text for Eikon:  ID:nGNX8VSFn2 
Further company coverage:  NGM.O 

 ((Reuters.Briefs@thomsonreuters.com;))